Merck Terminates Development and Commercialization Deal with Samsung Bioepis for Lusduna Nexvue (insulin glargine)

 Merck Terminates Development and Commercialization Deal with Samsung Bioepis for Lusduna Nexvue (insulin glargine)

Shots:

  • The termination of 2014 deal with Samsung, is the result of Lusduna Nexvue’s sales and production costs. Samsung receives $155M as total termination cost including investment and interest on it from Merck
  • The collaboration is response to the agreement in 2013 among Merck, Samsung Biologics and Samsung Bioepis to develop multiple biosimilar candidates across therapeutic areas
  • Lusduna Nexvue 100mg is a pre-filled device and received tentative approval from the US FDA indicated to treat diabetes

Click here to read full press release/ article | Ref: Merck | Image: Fastcompany

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post